Amiodarone Half-Life
The established elimination half-life of amiodarone is approximately 58 days (range: 20-77 days), making it one of the longest half-lives of any cardiovascular medication. 1
Key Pharmacokinetic Parameters
The elimination kinetics of amiodarone are extraordinarily complex and highly variable between patients:
- Terminal elimination half-life: Averages 58 days after chronic oral dosing 1
- Range of variability: 20-77 days across different studies 2
- More precise estimate from population pharmacokinetics: 55 days 3
This unusually long half-life results from amiodarone's slow release from lipid-rich tissues where it accumulates in high concentrations (fat, muscle, liver, lungs, and skin) 1.
Important Clinical Context
Acute vs. Chronic Dosing Differences
The half-life changes dramatically depending on duration of therapy:
- After single dose: Terminal half-life is only 24.1 ± 19.5 hours 4
- After one month of chronic dosing: Increases to 20.4 ± 4.8 days 4
- At steady state (long-term therapy): Reaches the full 55-58 days 1, 3
Active Metabolite (Desethylamiodarone)
The major metabolite DEA has similar pharmacokinetics:
- Terminal half-life of DEA: approximately 29.5 ± 9.7 days after chronic dosing 4
- DEA accumulates to plasma concentrations roughly equal to amiodarone itself during long-term therapy 1
Critical Clinical Implications
After discontinuation of chronic amiodarone therapy:
- 25% reduction in serum concentration occurs in approximately 3 days
- 50% reduction takes approximately 36 days 3
- Complete elimination may require 3-4 months in some patients 4
This extraordinarily long half-life means:
- Therapeutic effects persist for weeks to months after stopping the drug
- Adverse effects may emerge or persist long after discontinuation
- Drug interactions continue well beyond cessation of therapy 1
- Dose adjustments take weeks to months to reach new steady state
The FDA drug label confirms these parameters, noting that after 48 hours of IV infusion, mean serum concentrations are maintained, and the drug exhibits complex disposition with negligible renal excretion 5.